Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Venetoclax in patients with previously treated WM

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 499

Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA

Dr Castillo speaks with ecancer at EHA 23 about results from a prospective phase II study of venetoclax in previously treated Waldenström Macroglobulinemia (WM).

He describes the over expression of BCL2 in these cells, and the encouraging responses of a 90% response in IGM levels and reduction in blood marrow.

With venetoclax being well tolerated, Dr Castillo outlines future combinations and trial validation with larger patient cohorts.

For more in WM, watch Prof Meletios Dimopolous discuss the use of ibrutinib with chemotherapy in the iNNOVATE trial here.

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation